Evommune is set to make its stock market debut next week, but the biotech company is keeping investors guessing about its final share price.

Navan will be the first large company to debut without a fully functioning Securities and Exchange Commission.

Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 ...

Founded in 2022 by Population Health Partners and ARCH Venture Partners, the biotech venture giant led by Bob Nelsen, Metsera ...

Medline named multi-year preferred supplier deals, international expansion and takeovers as ways it will drive further growth ...

We’ve also seen investors lean into neurodegenerative and CNS conditions like schizophrenia. Karuna’s $14 billion acquisition ...

Pollon Life, a Chinese biotech company backed by Jack Ma’s Yunfeng Capital, has confidentially filed for a Hong Kong IPO that could raise about USD 300 million. The firm, maker of China’s first ...